Significance of antimicrobial synergism for the outcome of gram negative sepsis.
about
Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trialsBeta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis.Carbenicillin plus cefazolin with or without mecillinam as an early treatment of bacteremia caused by gram-negative organisms: randomized double-blind study.Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan.Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for ReComparative in vitro antimicrobial susceptibilities of nosocomial isolates of Acinetobacter baumannii and synergistic activities of nine antimicrobial combinations.Pharmacokinetics of cefoperazone and tobramycin alone and in combination.Evaluation of combination chemotherapy in a lightly anesthetized animal model of Pseudomonas pneumoniaProspective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients.Comparative synergistic activity of cefoperazone, cefotaxime, moxalactam, and carbenicillin, combined with tobramycin, against Pseudomonas aeruginosa.Imipenem-cilastatin versus sulbactam-cefoperazone plus amikacin in the initial treatment of febrile neutropenic cancer patients.Combination therapy for treatment of infections with gram-negative bacteria.Interpretation of the disk diffusion susceptibility test for amikacin: report of a collaborative study.Serum bactericidal testAntibiotic combinations: should they be tested?Antimicrobial agent therapy for Pseudomonas aeruginosa.Rapid diagnosis of Pseudomonas aeruginosa urinary tract infections by radioimmunoassay.Synergism at clinically attainable concentrations of aminoglycoside and beta-lactam antibiotics.Comparative in vitro synergistic activity of new beta-lactam antimicrobial agents and amikacin against Pseudomonas aeruginosa and Serratia marcescens.In vitro and in vivo studies of three antibiotic combinations against gram-negative bacteria and Staphylococcus aureus.Serum bactericidal activity of moxalactam and cefotaxime with and without tobramycin against Pseudomonas aeruginosa and Staphylococcus aureus.Methodological variation in antibiotic synergy tests against enterococci.Correlation of in vitro activities of cephalothin and ceftazidime with their efficacies in the treatment of Staphylococcus aureus endocarditis in rabbits.Serum bactericidal activity of ceftazidime and cefoperazone alone or in combination with amikacin against Pseudomonas aeruginosa and Klebsiella pneumoniae.Stability of gentamicin, tobramycin, and amikacin in combination with four beta-lactam antibiotics.In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa.In vitro activity of aztreonam in combination with newer beta-lactams and amikacin against multiply resistant gram-negative bacilli.Enhanced in vitro bactericidal activity of amikacin or gentamicin combined with three new extended-spectrum cephalosporins against cephalothin-resistant members of the family Enterobacteriaceae.Bactericidal and synergistic activity of moxalactam alone and in combination with gentamicin against Pseudomonas aeruginosa.
P2860
Q30756968-04A08CF7-A3BA-40B9-8379-E76F6ED66440Q31143077-1F8AF952-D25B-4F4E-997F-CF752D982A45Q33733238-39D2F2E8-2E10-4E94-8F61-88C15C8145D1Q34141308-381E6694-C700-4FC4-889B-7DAE006853EEQ35124179-61ED48AB-51BB-4105-941B-CBD828EFB78BQ35135561-B9DEA6D6-C43E-43E5-B5B9-C8EF01E0553BQ35536721-C33804D2-1BE1-464B-AF8D-71E7A3F4E9FEQ35537663-51B11FA9-66FD-4598-809E-A36CD6F10888Q35573306-8C0C0DEB-98FE-4E5D-94E6-7216D28EC02AQ35668893-C1B5570A-54D0-4191-AADF-A08C9C3A8D08Q35938407-6835D63C-D4F2-4AEC-B041-B88249895D20Q36156077-CE4E3F4A-84F6-4148-B244-FD80779DE768Q36479069-55C4B0C2-4456-4F19-890C-10B83F37EA19Q36632471-D4484316-2203-4B65-8135-ED835A6D96A0Q36632795-3D70BFC6-2195-4828-857C-596F5E8A9EC1Q36756391-DFBA594F-F608-4CE1-8476-90D3065E1516Q37313472-B6E6D4F0-0C58-4E64-8EEA-8184941A8223Q39849094-C16E5C12-DBB8-4B1F-BA15-3BFE3B57F678Q39855592-455865D6-84DF-4DAA-88E4-37537305F1E2Q39855851-66402F5D-EC95-4B51-9674-B82567E0C364Q39855920-3B03B85D-438F-45B0-ACF8-4EDC0FB4DE1BQ40231640-80B0847C-02E7-4F22-9E54-53C712529106Q40283340-FD533774-5086-4D29-9971-8A47E7A66F98Q41897674-83527F4A-5D60-4847-B239-AE7FC9D6621EQ41963259-41923C33-9B3F-45E9-9CD0-C54020F0759AQ42108953-89F905CF-9A12-47BA-9D83-599302D8BF6BQ42113634-CCA0EB9C-21FE-493B-9D1B-B98B04133847Q42250732-D34579C7-8025-4D39-A359-BB35A99EDFD9Q42928358-F7387A8F-478E-42FC-BE98-56453B239897
P2860
Significance of antimicrobial synergism for the outcome of gram negative sepsis.
description
1977 nî lūn-bûn
@nan
1977年の論文
@ja
1977年学术文章
@wuu
1977年学术文章
@zh-cn
1977年学术文章
@zh-hans
1977年学术文章
@zh-my
1977年学术文章
@zh-sg
1977年學術文章
@yue
1977年學術文章
@zh
1977年學術文章
@zh-hant
name
Significance of antimicrobial synergism for the outcome of gram negative sepsis.
@en
type
label
Significance of antimicrobial synergism for the outcome of gram negative sepsis.
@en
prefLabel
Significance of antimicrobial synergism for the outcome of gram negative sepsis.
@en
P2093
P1476
Significance of antimicrobial synergism for the outcome of gram negative sepsis.
@en
P2093
Klastersky J
Meunier-Carpentier F
Prevost JM
P304
P407
P577
1977-03-01T00:00:00Z